Lipocine (LPCN) Retained Earnings (2011 - 2025)
Lipocine's (LPCN) quarterly Retained Earnings came in at $223.9 million in Q4 2025, up 1.41% YoY from $220.8 million in Q4 2024, and up 1.22% on a QoQ basis from $221.2 million in Q3 2025.
Lipocine (LPCN) Retained Earnings (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Retained Earnings data on file, last reported at $223.9 million in Q4 2025.
- Quarterly Retained Earnings rose 1.41% year-over-year to $223.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $223.9 million (up 1.41% YoY) and the FY2025 annual result came in at $223.9 million, up 1.41% from the prior year.
- Retained Earnings climbed to $223.9 million in Q4 2025, from $221.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $223.9 million in Q4 2025 to a low of $217.8 million in Q1 2021.
- A 5-year average of $219.8 million and a median of $219.7 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 33.3% — and 2025, when it gained 0.19%.
- Tracing LPCN's Retained Earnings over 5 years: stood at $218.3 million in 2021, then advanced by 0.38% to $219.1 million in 2022, then increased by 0.48% to $220.2 million in 2023, then increased by 0.28% to $220.8 million in 2024, then climbed by 1.41% to $223.9 million in 2025.
- The last three Retained Earnings figures came in at $223.9 million (Q4 2025), $221.2 million (Q3 2025), and $221.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | 223.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 223.90 Mn |
| Sep 30, 2025 | 221.20 Mn |
| Jun 30, 2025 | 221.00 Mn |
| Mar 31, 2025 | 220.86 Mn |
| Dec 31, 2024 | 220.79 Mn |
| Sep 30, 2024 | 220.69 Mn |
| Jun 30, 2024 | 220.58 Mn |
| Mar 31, 2024 | 220.26 Mn |
| Dec 31, 2023 | 220.17 Mn |
| Sep 30, 2023 | 220.02 Mn |
| Jun 30, 2023 | 219.44 Mn |
| Mar 31, 2023 | 219.28 Mn |
| Dec 31, 2022 | 219.11 Mn |
| Sep 30, 2022 | 218.95 Mn |
| Jun 30, 2022 | 218.79 Mn |
| Mar 31, 2022 | 218.66 Mn |
| Dec 31, 2021 | 218.29 Mn |
| Sep 30, 2021 | 218.14 Mn |
| Jun 30, 2021 | 217.99 Mn |
| Mar 31, 2021 | 217.85 Mn |